The APP-BACE1-Fe65 complex is a critical ternary protein interaction that regulates the amyloidogenic processing of Amyloid Precursor Protein (APP) and drives the production of amyloid-beta (Aβ) peptides in Alzheimer's disease (AD). This complex represents a key therapeutic target for AD intervention.
APP is a type I transmembrane protein expressed predominantly in neurons. It undergoes two major processing pathways:
- Amyloidogenic pathway: β-secretase (BACE1) cleavage followed by γ-secretase cleavage, producing Aβ peptides
- Non-amyloidogenic pathway: α-secretase cleavage, producing sAPPα and preventing Aβ formation
BACE1 (also called BACE, ASP2,_MEMCAPSIN_1) is a transmembrane aspartyl protease that initiates the amyloidogenic cascade by cleaving APP at the β-secretase site (Met⁶⁷¹-Asp⁶⁷² in APP₇₇₀ isoform). BACE1 is upregulated in AD brains and represents a prime drug target.
Fe65 (APBB1, FE65, STAT3IP1) is a adaptor protein containing:
- WW domain: Binds to APP's YENPTY motif
- PTB domain: Binds to APP's intracellular domain (AICD)
- Two WW domains: Protein interaction modules
Fe65 acts as a molecular scaffold, bridging APP to other signaling .
graph TD
APP["APP<br/> transmembrane"] -->|"YENPTY motif"| Fe65["Fe65<br/> adaptor"]
APP -->|"β-secretase site"| BACE1["BACE1<br/> aspartyl protease"]
Fe65 -.->|interacts| BACE1["BACE1"]
BACE1 -->|"cleaves APP"| AICD["AICD<br/> intracellular domain"]
AICD -->|"translocates"| Nucleus["Nucleus"]
Fe65 -->|"recruits"| histoneAcet["Histone<br/> Acetyltransferases"]
Nucleus -->|"transcription"| TargetGenes["Target<br/> Genes"]
style APP fill:#f9f,stroke:#333
style BACE1 fill:#f96,stroke:#333
style Fe65 fill:#9f9,stroke:#333
style AICD fill:#ff9,stroke:#333
- Initial Binding: Fe65 binds to APP's YENPTY motif (residues 681-690) via its PTB domain
- Complex Formation: BACE1 binds to the extracellular domain of APP near the β-secretase cleavage site
- Scaffold Function: Fe65 simultaneously binds both APP and BACE1, forming a ternary complex
- Cleavage Enhancement: Fe65 binding allosterically enhances BACE1 enzymatic activity
- AICD Release: BACE1 cleavage releases the AICD fragment
- Nuclear Signaling: Fe65-AICD complex translocates to the nucleus
- Transcriptional Regulation: Fe65 recruits histone acetyltransferases to regulate gene expression
- Fe65 Upregulation: Fe65 expression increases in AD brain, enhancing BACE1 cleavage
- Phosphorylation: Fe65 phosphorylation at tyrosine residues increases APP binding affinity
- Trafficking: The complex localizes to lipid rafts where BACE1 activity is highest
- sAPPα Competition: Soluble APPα (from non-amyloidogenic pathway) can displace Fe65
- BACE1 Inhibitors: Small molecule inhibitors block the proteolytic activity
- Gamma-Secretase Modulators: Modulators shift γ-secretase cleavage toward shorter Aβ species
Multiple BACE1 inhibitor programs have advanced to clinical trials:
| Compound |
Developer |
Stage |
Notes |
| Verubecestat (MK-8931) |
Merck |
Phase III |
Halted due to cognitive decline |
| Atabecestat (LY2881836) |
Eli Lilly |
Phase II |
Halted for liver toxicity |
| CNP520 |
Novartis |
Phase II/III |
Cancelled for safety |
Fe65 represents an alternative target:
- Disrupt Fe65-APP binding: PTB domain inhibitors
- Block Fe65-BACE1 interaction: Allosteric modulators
- Gene therapy: Reduce Fe65 expression
- APP Amyloid Pathway — Overview of APP processing
- BACE1 Amyloidogenic Cleavage — BACE1 mechanism
- Aβ Toxicity Mechanisms — Downstream effects
- Gamma-Secretase Complex — Sequential cleavage
- Zhang et al., APP-Fe65 complex in Alzheimer's disease (2024)
- Caille et al., Fe65 modulates BACE1 activity (2004)
- Hebert et al., BACE1 coordinate regulation (2008)
- Wan et al., Fe65-APP nuclear signaling (2015)
- Evin et al., BACE1 inhibitors clinical trials (2020)